1042434-76-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
BenzaMide, 2-[(2,5-dichloro-4-pyrimidinyl)amino]-, is used as a research compound for the development of new pharmaceuticals. Its unique structure and properties make it a valuable tool in medicinal chemistry, where it can be studied for potential therapeutic effects against various diseases and conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, BenzaMide, 2-[(2,5-dichloro-4-pyrimidinyl)amino]-, is employed as a chemical building block for the synthesis of novel compounds with potential therapeutic applications. Its pyrimidine ring and chlorine-substituted structure offer a versatile platform for the design and optimization of new drugs.
Used in Disease Treatment Research:
Although further research is needed, BenzaMide, 2-[(2,5-dichloro-4-pyrimidinyl)amino]-, may have potential applications in the treatment of various diseases and conditions. Its unique chemical properties could contribute to the development of new therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Synthesis:
BenzaMide, 2-[(2,5-dichloro-4-pyrimidinyl)amino]-, is also used in chemical synthesis processes, where it can be incorporated into more complex molecules or used as an intermediate in the production of other pharmaceutical compounds.

Upstream product

• 5750-76-5 2,4,5-trichloropyrimidine 
• 28144-70-9 anthranilic acid amide 

Downstream Products

• 1022954-56-8 2-[5-chloro-2-(1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-ylamino)-pyrimidin-4-ylamino]-benzamide 
• 1089653-51-9 2-{[5-chloro-2-(3-isoxazolylamino)-4-pyrimidinyl]amino}benzamide 

Relevant academic research and scientific papers

Compound used as ALK (anaplastic lymphoma kinase) inhibitor and application thereof

The invention discloses a compound shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, solvates or predrugs. The symptoms are defined in claim requirements. The compound shownin the formula I has good inhibiting activity on ALK (anaplastic lymphoma kinase), and can be used for preparing medicines for adjusting the activity of the ALK activity or treating the ALK-related diseases, especially nonsmall-cell lung cancer drugs. (The formula I is shown in the attached figure.).

Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e.g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen.

ANTHRANILAMIDE INHIBITORS OF AURORA KINASE

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

ANTHRANILAMIDES

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, and Het are as defined herein. Compounds of the present invention are useful as Aurora kinase inhibitors.